Floatz logo

Albuterol

Asthma

Tongji UniversitySmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Asthma cohort.

Asset / SponsorPhaseRating
Budesonide
New York City Health and Hospitals Corporation
Phase 4BBB
SALMETEROL
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 4BBB
Montelukast
Kafrelsheikh University
Phase 4BBB
Flixotide
GlaxoSmithKline
Phase 4BBB
MK-0476
Organon and Co
Phase 4BB

View all 48 →

Same molecule, other indications

Albuterol is also rated in:

glycogen storage disease IIDormant
BBB
Indicative ·
72 / 100
View asset →
childhood onset asthmaDormant
BB
Indicative ·
65 / 100
View asset →
Dyspnea; AsthmaticDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →